WHO grants emergency use listing to Bharat Biotech's Covaxin

06:26 PM Nov 03, 2021 | PTI |

New Delhi: In a major development, the WHO on Wednesday said it has granted emergency use listing (EUL) to Bharat Biotech’s COVID-19 vaccine Covaxin.


This comes after the Technical Advisory Group (TAG), an independent advisory committee of WHO-recommended EUL status for Covaxin.

”WHO has granted emergency use listing (EUL) to #COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19,” the global health body said in a tweet.


Dr Poonam Khetarpal Singh, Regional Director of WHO Southeast Asia, in a tweet, said, ”Congratulations India for Emergency Use Listing of its indigenously produced COVID-19 vaccine Covaxin.” ”The Technical Advisory Group of WHO has recommended Emergency Use Listing status for Covaxin,” a source told PTI before the WHO announcement.


The TAG on October 26 had sought ”additional clarifications” from the company for Covaxin to conduct a final ”risk-benefit assessment” for Emergency Use Listing of the vaccine.

Prime Minister Narendra Modi met WHO Director-General Dr. Tedros Adhanom Ghebreyesus at the G20 summit recently.

The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.

Covaxin has demonstrated 77.8 percent effectiveness against symptomatic COVID-19 and 65.2 percent protection against the new Delta variant. In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.


Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.